Exjade(R) (deferasirox, ICL670) in the Treatment of Chronic Iron Overload Associated with Blood Transfusion

Overview

Journal Ther Clin Risk Manag

Publisher Dove Medical Press

Date 2008 Mar 25

PMID 18360637

Citations 25

Authors

Maria Domenica Cappellini

Affiliations

Soon will be listed here.

Abstract

Although blood transfusions are important for patients with anemia, chronic transfusions inevitably lead to iron overload as humans cannot actively remove excess iron. The cumulative effects of iron overload lead to significant morbidity and mortality, if untreated. Although the current reference standard iron chelator deferoxamine has been used clinically for over four decades, its effectiveness is limited by a demanding therapeutic regimen that leads to poor compliance. Deferasirox (Exjade(R), ICL670, Novartis Pharma AG, Basel, Switzerland) is a once-daily, oral iron chelator approved for the treatment of transfusional iron overload in adult and pediatric patients. The efficacy and safety of deferasirox have been established in a comprehensive clinical development program involving patients with various transfusion-dependent anemias. Deferasirox has a dose-dependent effect on iron burden, and is as efficacious as deferoxamine at comparable therapeutic doses. Deferasirox therapy can be tailored to a patient's needs, as response is related to both dose and iron intake. Since deferasirox has a long half-life and is present in the plasma for 24 hours with once-daily dosing, it is unique in providing constant chelation coverage with a single dose. The availability of this convenient, effective, and well tolerated therapy represents a significant advance in the management of transfusional iron overload.

Citing Articles

Sex and Gender Differences in Iron Chelation.

Allegra S, Comita S, Roetto A, De Francia S Biomedicines. 2025; 12(12.

PMID: 39767791 PMC: 11673655. DOI: 10.3390/biomedicines12122885.

Deferasirox and Ciprofloxacin: Potential Ternary Complex Formation With Ferric Iron, Pharmacodynamic, and Pharmacokinetic Interactions.

Hamdan I, Tarawneh R, Awwadi F, Al-Qattan D, Hamdan A, Afifi F ScientificWorldJournal. 2024; 2024:9309491.

PMID: 39649814 PMC: 11623990. DOI: 10.1155/tswj/9309491.

Comparison of oral iron chelators in the management of transfusion-dependent β-thalassemia major based on serum ferritin and liver enzymes.

Yusuf S, Herdata H, Edward E, Khairunnisa K F1000Res. 2024; 12:154.

PMID: 39233713 PMC: 11372351. DOI: 10.12688/f1000research.128810.2.

Disrupting iron homeostasis can potentiate colistin activity and overcome colistin resistance mechanisms in Gram-Negative Bacteria.

Gadar K, de Dios R, Kaderabkova N, Prescott T, Mavridou D, McCarthy R Commun Biol. 2023; 6(1):937.

PMID: 37704838 PMC: 10499790. DOI: 10.1038/s42003-023-05302-2.

ATF4-activated parkin induction contributes to deferasirox-mediated cytoprotection in Parkinson's disease.

Ham S, Kim J, Kim H, Shin J, Lee Y Toxicol Res. 2023; 39(2):191-199.

PMID: 37008698 PMC: 10050497. DOI: 10.1007/s43188-022-00157-x.

References

Hershko C, Hoffbrand A, Kosaryan M, Olivieri N, Tondury P, Wonke B . Results of long-term deferiprone (L1) therapy: a report by the International Study Group on Oral Iron Chelators. Br J Haematol. 1995; 91(1):224-9. DOI: 10.1111/j.1365-2141.1995.tb05274.x. View

Galanello R, Piga A, Forni G, Bertrand Y, Foschini M, Bordone E . Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major. Haematologica. 2006; 91(10):1343-51. View

Hershko C, Konijn A, Nick H, Breuer W, Cabantchik Z, Link G . ICL670A: a new synthetic oral chelator: evaluation in hypertransfused rats with selective radioiron probes of hepatocellular and reticuloendothelial iron stores and in iron-loaded rat heart cells in culture. Blood. 2001; 97(4):1115-22. DOI: 10.1182/blood.v97.4.1115. View

Galanello R, Piga A, Alberti D, Rouan M, Bigler H, Sechaud R . Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to beta-thalassemia. J Clin Pharmacol. 2003; 43(6):565-72. View

Ishizaka N, Saito K, Mitani H, Yamazaki I, Sata M, Usui S . Iron overload augments angiotensin II-induced cardiac fibrosis and promotes neointima formation. Circulation. 2002; 106(14):1840-6. DOI: 10.1161/01.cir.0000031161.77536.02. View

Greenberg P, Baer M, Bennett J, Bloomfield C, de Castro C, Deeg H . Myelodysplastic syndromes clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2006; 4(1):58-77. View

Cappellini M, Cohen A, Piga A, Bejaoui M, Perrotta S, Agaoglu L . A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood. 2005; 107(9):3455-62. DOI: 10.1182/blood-2005-08-3430. View

Pennell D, Berdoukas V, Karagiorga M, Ladis V, Piga A, Aessopos A . Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood. 2005; 107(9):3738-44. DOI: 10.1182/blood-2005-07-2948. View

Olivieri N, Nathan D, MacMillan J, Wayne A, Liu P, McGee A . Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med. 1994; 331(9):574-8. DOI: 10.1056/NEJM199409013310903. View

10.

Modell B, Khan M, Darlison M . Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet. 2000; 355(9220):2051-2. DOI: 10.1016/S0140-6736(00)02357-6. View

11.

Piga A, Galanello R, Forni G, Cappellini M, Origa R, Zappu A . Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica. 2006; 91(7):873-80. View

12.

Cunningham M, Macklin E, Neufeld E, Cohen A . Complications of beta-thalassemia major in North America. Blood. 2004; 104(1):34-9. DOI: 10.1182/blood-2003-09-3167. View

13.

Nisbet-Brown E, Olivieri N, Giardina P, Grady R, Neufeld E, Sechaud R . Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet. 2003; 361(9369):1597-602. DOI: 10.1016/S0140-6736(03)13309-0. View

14.

Nick H, Wong A, Acklin P, Faller B, Jin Y, Lattmann R . ICL670A: preclinical profile. Adv Exp Med Biol. 2003; 509:185-203. DOI: 10.1007/978-1-4615-0593-8_10. View

15.

Cabantchik Z, Breuer W, Zanninelli G, Cianciulli P . LPI-labile plasma iron in iron overload. Best Pract Res Clin Haematol. 2005; 18(2):277-87. DOI: 10.1016/j.beha.2004.10.003. View

16.

Borgna-Pignatti C, Cappellini M, De Stefano P, Del Vecchio G, Forni G, Gamberini M . Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood. 2005; 107(9):3733-7. DOI: 10.1182/blood-2005-07-2933. View

17.

Cighetti G, Duca L, Bortone L, Sala S, Nava I, Fiorelli G . Oxidative status and malondialdehyde in beta-thalassaemia patients. Eur J Clin Invest. 2002; 32 Suppl 1:55-60. DOI: 10.1046/j.1365-2362.2002.0320s1055.x. View

18.

Brittenham G, Griffith P, Nienhuis A, McLaren C, Young N, Tucker E . Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med. 1994; 331(9):567-73. DOI: 10.1056/NEJM199409013310902. View

19.

De Luca C, Filosa A, Grandinetti M, Maggio F, Lamba M, Passi S . Blood antioxidant status and urinary levels of catecholamine metabolites in beta-thalassemia. Free Radic Res. 1999; 30(6):453-62. DOI: 10.1080/10715769900300491. View

20.

Hoffbrand A, Cohen A, Hershko C . Role of deferiprone in chelation therapy for transfusional iron overload. Blood. 2003; 102(1):17-24. DOI: 10.1182/blood-2002-06-1867. View